Similar anti-viral opportunities are also seen in PB1–PB2
interactions, since the crystal structure of the binding interface of
PB1–PB2 shows that only a small section of PB1 (residues 678–
757) and of PB2 (residues 1–37) are involved in the interface90. To
date, several synthetic-peptide-based inhibitors have been reported
to be able to interfere with PB1–PB2 interactions and disrupt
normal function of the polymerase91,92. However, nonpeptide